{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:47:09Z","timestamp":1791888429049,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ygyno.2013.02.023","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T21:49:43Z","timestamp":1361828983000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"title":["Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial"],"prefix":"10.1016","volume":"129","author":[{"given":"Louise A.","family":"Brinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"McMeekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Creasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi S.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Soslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Zaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.02.023_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/modpathol.3880051","article-title":"Theories of endometrial carcinogenesis: a multidisciplinary approach","volume":"13","author":"Sherman","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0015","series-title":"Blaustein's pathology of the female genital tract","first-page":"359","article-title":"Precursor lesions of endometrial carcinoma","author":"Ellenson","year":"2012"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0020","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/0046-8177(95)90203-1","article-title":"Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation","volume":"26","author":"Ambros","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/00313025.2010.520307","article-title":"Current concepts in the pathology and epigenetics of endometrial carcinoma","volume":"42","author":"Arafa","year":"2010","journal-title":"Pathology"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.semdp.2010.09.004","article-title":"Nonendometrioid endometrial carcinomas","volume":"27","author":"Lim","year":"2010","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0035","first-page":"1851","article-title":"Factors associated with type I and type II endometrial cancer","volume":"21","author":"Felix","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/jwh.2010.2529","article-title":"Trends in endometrial cancer incidence rates in the United States, 1999\u20132006","volume":"20","author":"Duong","year":"2011","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0045","first-page":"963","article-title":"Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas","volume":"10","author":"Sherman","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/aje\/kws200","article-title":"Endometrial cancer risk factors by 2 main histologic subtypes in the NIH-AARP Diet and Health Study","volume":"177","author":"Yang","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/gyno.1998.4941","article-title":"Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors","volume":"69","author":"Zelmanowicz","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0b013e3181846c6d","article-title":"FIGO staging of endometrial adenocarcinoma: a critical review and proposal","volume":"28","author":"Zaino","year":"2009","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0070","series-title":"Applied logistic regression","author":"Hosmer","year":"2000"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0075","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1055-9965.EPI-10-0742","article-title":"What can we learn about disease etiology from case\u2013case analyses? Lessons from breast cancer","volume":"19","author":"Martinez","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2009.06.011","article-title":"Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review","volume":"115","author":"Boruta","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ygyno.2009.07.030","article-title":"An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)","volume":"115","author":"Fader","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/107327480901600107","article-title":"Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes","volume":"16","author":"Mendivil","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/jwh.2008.1171","article-title":"Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001\u20132003","volume":"18","author":"Sabatino","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0100","first-page":"1213","article-title":"Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma","volume":"27","author":"Sagr","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/cncr.11484","article-title":"Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus","volume":"98","author":"Sherman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2011.07.030","article-title":"Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer\u2014a clinical and pathological evaluation","volume":"124","author":"Voss","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00428-010-0939-z","article-title":"Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study","volume":"457","author":"Zannoni","year":"2010","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0120","doi-asserted-by":"crossref","first-page":"139.e1","DOI":"10.1016\/j.ajog.2007.01.019","article-title":"Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer","volume":"197","author":"Doherty","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0125","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1055-9965.EPI-05-0111","article-title":"Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women","volume":"14","author":"Lacey","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1055-9965.EPI-09-0712","article-title":"Long-term postmenopausal hormone therapy and endometrial cancer","volume":"19","author":"Razavi","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0135","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/oby.2006.191","article-title":"Relation of BMI and physical activity to sex hormones in postmenopausal women","volume":"14","author":"McTiernan","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0140","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ajog.2011.05.042","article-title":"Understanding obesity and endometrial cancer risk: opportunities for prevention","volume":"205","author":"Schmandt","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0145","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/ijc.22260","article-title":"Body size in relation to cancer of the uterine corpus in 1million Norwegian women","volume":"120","author":"Bjorge","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0155","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.bjc.6605158","article-title":"The impact of BMI on subgroups of uterine cancer","volume":"101","author":"Lindemann","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1158\/1055-9965.EPI-07-2567","article-title":"Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype","volume":"17","author":"McCullough","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0165","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/EDE.0b013e3182263018","article-title":"Pregnancy history and risk of endometrial cancer","volume":"22","author":"Pocobelli","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0170","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ejca.2009.11.015","article-title":"Active and passive cigarette smoking and the risk of endometrial cancer in Poland","volume":"46","author":"Yang","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0175","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jn\/136.6.1588","article-title":"Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial\/ethnic population of women","volume":"136","author":"Sowers","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0180","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-10-0832","article-title":"Body mass index, hormone replacement therapy and endometrial cancer risk: a meta-analysis","author":"Crosbie","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","article-title":"Breast cancer risk factors and second primary malignancies among women with breast cancer","volume":"105","author":"Trentham-Dietz","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0190","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2006.01.014","article-title":"Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?","volume":"102","author":"Chan","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0195","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2004.04.009","article-title":"Association between uterine serous carcinoma and breast cancer","volume":"94","author":"Gehrig","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0200","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ijc.25395","article-title":"Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55years old or younger","volume":"128","author":"Liang","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0205","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases","volume":"91","author":"Slomovitz","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0210","first-page":"1531","article-title":"BRCA germline mutations in women with uterine serous carcinoma\u2014still a debate","volume":"20","author":"Lavie","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0215","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0220","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1994.1271","article-title":"Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features","volume":"55","author":"Barakat","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0225","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","article-title":"Relationship between tamoxifen use and high risk endometrial cancer histologic types","volume":"112","author":"Bland","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/jnci\/djh007","article-title":"Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer","volume":"96","author":"Curtis","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0240","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-007-9823-1","article-title":"Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer","volume":"112","author":"Hoogendoorn","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0245","first-page":"2015","article-title":"Long-term tamoxifen treatment: a possible aetiological factor in the development of uterine carcinosarcoma: two case-reports and review of the literature","volume":"20","author":"Fotiou","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2013.02.023_bb0250","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0046-8177(03)00335-6","article-title":"Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: report of 5 cases, including 2 associated with tamoxifen therapy","volume":"34","author":"McCluggage","year":"2003","journal-title":"Hum Pathol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813000942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813000942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:32:29Z","timestamp":1758771149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813000942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0090825813000942"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.02.023","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}